Circulating Endothelial Compartment During Normal and Pathological Aging

NCT01038700 | Completed

• 1 other identifier: P070801
• Study Type: observational
• Target: 84
• Locations: 1 country
• Sites: 1

Brief Summary

This part of the project aims to describe changes in markers of vascular competence (Endothelial Microparticles Platelet (EMP), Circulating endothelial cells (CEC) and Circulating endothelial progenitors (EPC)) at different ages of lifespan both in physiological state and in response to hypoxia-induced vascular stress.

Conditions

Healthy

Keywords

Circulating endothelial compartment; microparticles; endothelial progenitors cells; circulating endothelial cells; transcriptome; aging; Healthy volunteers

Outcome Measures

Primary Outcomes (1)

• Analyse of CEC, EMP and EPC at different ages of lifespan both in physiological state and in response to an hypoxia- induced vascular stress

  3 days

Secondary Outcomes (1)

• Transcriptome analysis on EPC isolated from cord blood and peripheral blood from young and old adults

  end

Eligibility Criteria

• Age: 10 Years - 90 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

healthy volunteers

You may qualify if:

• Healthy volunteers of 20-30 and 60-70 years old
• Non smokers male
• Biological test in normal values : lipids, glucose, TGO, TGT, alkaline phosphatases, gamma-GT, bilirubin, creatinine, ionogram, Ca++, albumin, proteins, WBC, platelets count, coagulation tests (APTT, PT, Fibrinogen).
• Negative HIV1 and 2, HBV (Hbs antigen) and HCV serology.
• Normal ECG 12 derivations, arterial pressure and cardiac frequency.

You may not qualify if:

• Evaluative disease in the past 10 days
• Hemorrhagic disorders
• Treatments with antiplatelets agents, oral or injectable anticoagulant
• Statins, glitazones, EPO, G-CSF
• Frequent faintness
• Blood donation in the 3 months preceding the study
• Refusal or linguistic or psychic incapacity to sign the enlightened consent
• Biological parameters apart from the usual values of the healthy subject (Hb\<10 g/dL, TGO/TGT \> 2 times higher limit of normal values)
• Prone not being able to subject to the constraints protocol (for example, not cooperating, incompetent to go to the visits of follow-up and probably incompetent to finish the study).

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead
• Fondation pour la Recherche Médicale: collaborator
• Assistance Publique Hopitaux De Marseille: collaborator
• Institut National de la Santé Et de la Recherche Médicale, France: collaborator

Study Sites (1)

Hegp- Cic

Paris, France

Location

Related Publications (2)

• HoWangYin KY, Loinard C, Bakker W, Guerin CL, Vilar J, d'Audigier C, Mauge L, Bruneval P, Emmerich J, Levy BI, Pouyssegur J, Smadja DM, Silvestre JS. HIF-prolyl hydroxylase 2 inhibition enhances the efficiency of mesenchymal stem cell-based therapies for the treatment of critical limb ischemia. Stem Cells. 2014 Jan;32(1):231-43. doi: 10.1002/stem.1540.

  PMID: 24105925 DERIVED

• Evrard SM, d'Audigier C, Mauge L, Israel-Biet D, Guerin CL, Bieche I, Kovacic JC, Fischer AM, Gaussem P, Smadja DM. The profibrotic cytokine transforming growth factor-beta1 increases endothelial progenitor cell angiogenic properties. J Thromb Haemost. 2012 Apr;10(4):670-9. doi: 10.1111/j.1538-7836.2012.04644.x.

  PMID: 22284809 DERIVED

Biospecimen

Retention: SAMPLES WITHOUT DNA

whole blood

Study Officials

• David SMADJA, PH

  Assistance Publique - Hôpitaux de Paris

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: December 22, 2009
• First Posted: December 24, 2009
• Study Start: December 1, 2008
• Primary Completion: August 1, 2009
• Study Completion: September 1, 2010
• Last Updated: October 1, 2015

Record last verified: 2015-09

Locations

FR (1)